Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/patent-war-over-drugs-goes-chronic-rupali-mukherjee-20215/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/patent-war-over-drugs-goes-chronic-rupali-mukherjee-20215/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/patent-war-over-drugs-goes-chronic-rupali-mukherjee-20215/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/patent-war-over-drugs-goes-chronic-rupali-mukherjee-20215/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f5dc1ed9e80-trace').style.display = (document.getElementById('cakeErr67f5dc1ed9e80-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f5dc1ed9e80-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f5dc1ed9e80-code').style.display = (document.getElementById('cakeErr67f5dc1ed9e80-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f5dc1ed9e80-context').style.display = (document.getElementById('cakeErr67f5dc1ed9e80-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f5dc1ed9e80-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f5dc1ed9e80-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 20074,
		&#039;title&#039; =&gt; &#039;Patent war over drugs goes chronic -Rupali Mukherjee&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;MUMBAI: &lt;/em&gt;Turf war between Big Pharma and generic companies, which was largely restricted to exorbitantly priced life-saving drugs for cancer and HIV, is now spilling over to other chronic ailments like diabetes, and threatening to change dynamics of the nearly Rs 70,000 crore Indian pharma market.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Triggering a full-blown patent fight with US-based Merck, domestic generic company Glenmark has launched a more affordable version of the multinational&#039;s blockbuster anti-diabetes drug Januvia. The move is expected to heighten tensions between MNCs and domestic generic companies which have been embroiled in patent disputes over the last couple of years.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Glenmark&#039;s launch could also throw up a different patent challenge for the regulators, which have seen two prominent cases where the compulsory licence route was used to launch life-saving drugs at just a fraction of the original price. 
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Glenmark has priced its diabetes drug around 30% cheaper than Merck&#039;s Januvia, and the savings to patients could be nearly Rs 5,000 a year.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Merck&#039;s diabetes therapies Januvia and Janumet, launched in the Indian market in 2008, are part of the &#039;gliptin&#039; family. The drugs together are nearly Rs 200-crore brands, making them one of the fastest growing medicines, and are ranked No. 2 in the oral diabetics market (according to IMS data).
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Confirming the move, a company official said, &amp;quot;Glenmark is a responsible company and has launched the products after due diligence and research. Like other branded generics, Glenmark&#039;s Zita &amp;amp; Zita-Met are also branded generics.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The &#039;gliptin&#039; market in India is estimated at around Rs 500 crore, growing at 25% per year. &#039;Gliptin&#039; is an oral once-a-day treatment option. Priced at Rs 43 per tablet, a month&#039;s dose of Merck&#039;s Januvia costs nearly Rs 1,300. Though &#039;gliptins&#039; have emerged as a good option in diabetes treatment, their use has been restricted largely because of their high prices, experts say.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
A MSD India official said; &amp;quot;We are disappointed in Glenmark&#039;s decision to introduce products that directly infringe upon our intellectual property. We believe our patents for Januvia and Janumet are valid and enforceable and will vigorously defend them. Strong intellectual property protection is essential for growing India&#039;s innovative capacity and economic growth. As an innovative pharmaceutical company, protection of our intellectual property is vital to ensuring that we continue to assume the tremendous monetary risks associated with the discovery of innovative medicines.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In India, where there are over 65 million people with type 2 diabetes, MSD also has a comprehensive strategy to help address the challenge of reducing disease burden and to increase access to our medicines, including India-specific responsible pricing for Januvia and Janumet, the official added.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
While Glenmark says that its product is &amp;quot;non-infringing&amp;quot; on Merck&#039;s drug, the details of Merck&#039;s patent on the drug sold in the market, were not available. Experts say that Glenmark&#039;s move will lead to a protracted legal battle with both sides sticking to their point.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Leena Menghaney, legal expert and campaign coordinator for Medicins Sans Frontieres, a medical humanitarian NGO, says &amp;quot;Access issues are also present in non-communicable lifestyle ailments. This becomes more relevant since developing countries are witnessing an increasing burden of non-communicable diseases, including heart disease, cancer, diabetes, and chronic obstructive pulmonary disease. Hence, generic companies have a big role to play to bring down prices of drugs used in these ailments.&amp;quot; 
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Times of India, 1 April, 2013, http://timesofindia.indiatimes.com/business/india-business/Patent-war-over-drugs-goes-chronic/articleshow/19315419.cms&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;patent-war-over-drugs-goes-chronic-rupali-mukherjee-20215&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 20215,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 20074,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Patent war over drugs goes chronic -Rupali Mukherjee&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;diabetes,medicines,patents,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Times of India



MUMBAI: Turf war between Big Pharma and generic companies, which was largely restricted to exorbitantly priced life-saving drugs for cancer and HIV, is now spilling over to other chronic ailments like diabetes, and threatening to change dynamics...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;MUMBAI: &lt;/em&gt;Turf war between Big Pharma and generic companies, which was largely restricted to exorbitantly priced life-saving drugs for cancer and HIV, is now spilling over to other chronic ailments like diabetes, and threatening to change dynamics of the nearly Rs 70,000 crore Indian pharma market.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Triggering a full-blown patent fight with US-based Merck, domestic generic company Glenmark has launched a more affordable version of the multinational&#039;s blockbuster anti-diabetes drug Januvia. The move is expected to heighten tensions between MNCs and domestic generic companies which have been embroiled in patent disputes over the last couple of years.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Glenmark&#039;s launch could also throw up a different patent challenge for the regulators, which have seen two prominent cases where the compulsory licence route was used to launch life-saving drugs at just a fraction of the original price. &lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Glenmark has priced its diabetes drug around 30% cheaper than Merck&#039;s Januvia, and the savings to patients could be nearly Rs 5,000 a year.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Merck&#039;s diabetes therapies Januvia and Janumet, launched in the Indian market in 2008, are part of the &#039;gliptin&#039; family. The drugs together are nearly Rs 200-crore brands, making them one of the fastest growing medicines, and are ranked No. 2 in the oral diabetics market (according to IMS data).&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Confirming the move, a company official said, &amp;quot;Glenmark is a responsible company and has launched the products after due diligence and research. Like other branded generics, Glenmark&#039;s Zita &amp;amp; Zita-Met are also branded generics.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The &#039;gliptin&#039; market in India is estimated at around Rs 500 crore, growing at 25% per year. &#039;Gliptin&#039; is an oral once-a-day treatment option. Priced at Rs 43 per tablet, a month&#039;s dose of Merck&#039;s Januvia costs nearly Rs 1,300. Though &#039;gliptins&#039; have emerged as a good option in diabetes treatment, their use has been restricted largely because of their high prices, experts say.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;A MSD India official said; &amp;quot;We are disappointed in Glenmark&#039;s decision to introduce products that directly infringe upon our intellectual property. We believe our patents for Januvia and Janumet are valid and enforceable and will vigorously defend them. Strong intellectual property protection is essential for growing India&#039;s innovative capacity and economic growth. As an innovative pharmaceutical company, protection of our intellectual property is vital to ensuring that we continue to assume the tremendous monetary risks associated with the discovery of innovative medicines.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In India, where there are over 65 million people with type 2 diabetes, MSD also has a comprehensive strategy to help address the challenge of reducing disease burden and to increase access to our medicines, including India-specific responsible pricing for Januvia and Janumet, the official added.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;While Glenmark says that its product is &amp;quot;non-infringing&amp;quot; on Merck&#039;s drug, the details of Merck&#039;s patent on the drug sold in the market, were not available. Experts say that Glenmark&#039;s move will lead to a protracted legal battle with both sides sticking to their point.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Leena Menghaney, legal expert and campaign coordinator for Medicins Sans Frontieres, a medical humanitarian NGO, says &amp;quot;Access issues are also present in non-communicable lifestyle ailments. This becomes more relevant since developing countries are witnessing an increasing burden of non-communicable diseases, including heart disease, cancer, diabetes, and chronic obstructive pulmonary disease. Hence, generic companies have a big role to play to bring down prices of drugs used in these ailments.&amp;quot; &lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 20074,
	&#039;title&#039; =&gt; &#039;Patent war over drugs goes chronic -Rupali Mukherjee&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;MUMBAI: &lt;/em&gt;Turf war between Big Pharma and generic companies, which was largely restricted to exorbitantly priced life-saving drugs for cancer and HIV, is now spilling over to other chronic ailments like diabetes, and threatening to change dynamics of the nearly Rs 70,000 crore Indian pharma market.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Triggering a full-blown patent fight with US-based Merck, domestic generic company Glenmark has launched a more affordable version of the multinational&#039;s blockbuster anti-diabetes drug Januvia. The move is expected to heighten tensions between MNCs and domestic generic companies which have been embroiled in patent disputes over the last couple of years.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Glenmark&#039;s launch could also throw up a different patent challenge for the regulators, which have seen two prominent cases where the compulsory licence route was used to launch life-saving drugs at just a fraction of the original price. 
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Glenmark has priced its diabetes drug around 30% cheaper than Merck&#039;s Januvia, and the savings to patients could be nearly Rs 5,000 a year.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Merck&#039;s diabetes therapies Januvia and Janumet, launched in the Indian market in 2008, are part of the &#039;gliptin&#039; family. The drugs together are nearly Rs 200-crore brands, making them one of the fastest growing medicines, and are ranked No. 2 in the oral diabetics market (according to IMS data).
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Confirming the move, a company official said, &amp;quot;Glenmark is a responsible company and has launched the products after due diligence and research. Like other branded generics, Glenmark&#039;s Zita &amp;amp; Zita-Met are also branded generics.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The &#039;gliptin&#039; market in India is estimated at around Rs 500 crore, growing at 25% per year. &#039;Gliptin&#039; is an oral once-a-day treatment option. Priced at Rs 43 per tablet, a month&#039;s dose of Merck&#039;s Januvia costs nearly Rs 1,300. Though &#039;gliptins&#039; have emerged as a good option in diabetes treatment, their use has been restricted largely because of their high prices, experts say.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
A MSD India official said; &amp;quot;We are disappointed in Glenmark&#039;s decision to introduce products that directly infringe upon our intellectual property. We believe our patents for Januvia and Janumet are valid and enforceable and will vigorously defend them. Strong intellectual property protection is essential for growing India&#039;s innovative capacity and economic growth. As an innovative pharmaceutical company, protection of our intellectual property is vital to ensuring that we continue to assume the tremendous monetary risks associated with the discovery of innovative medicines.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In India, where there are over 65 million people with type 2 diabetes, MSD also has a comprehensive strategy to help address the challenge of reducing disease burden and to increase access to our medicines, including India-specific responsible pricing for Januvia and Janumet, the official added.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
While Glenmark says that its product is &amp;quot;non-infringing&amp;quot; on Merck&#039;s drug, the details of Merck&#039;s patent on the drug sold in the market, were not available. Experts say that Glenmark&#039;s move will lead to a protracted legal battle with both sides sticking to their point.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Leena Menghaney, legal expert and campaign coordinator for Medicins Sans Frontieres, a medical humanitarian NGO, says &amp;quot;Access issues are also present in non-communicable lifestyle ailments. This becomes more relevant since developing countries are witnessing an increasing burden of non-communicable diseases, including heart disease, cancer, diabetes, and chronic obstructive pulmonary disease. Hence, generic companies have a big role to play to bring down prices of drugs used in these ailments.&amp;quot; 
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Times of India, 1 April, 2013, http://timesofindia.indiatimes.com/business/india-business/Patent-war-over-drugs-goes-chronic/articleshow/19315419.cms&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;patent-war-over-drugs-goes-chronic-rupali-mukherjee-20215&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 20215,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 20074
$metaTitle = &#039;LATEST NEWS UPDATES | Patent war over drugs goes chronic -Rupali Mukherjee&#039;
$metaKeywords = &#039;diabetes,medicines,patents,Health&#039;
$metaDesc = &#039;
-The Times of India



MUMBAI: Turf war between Big Pharma and generic companies, which was largely restricted to exorbitantly priced life-saving drugs for cancer and HIV, is now spilling over to other chronic ailments like diabetes, and threatening to change dynamics...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;MUMBAI: &lt;/em&gt;Turf war between Big Pharma and generic companies, which was largely restricted to exorbitantly priced life-saving drugs for cancer and HIV, is now spilling over to other chronic ailments like diabetes, and threatening to change dynamics of the nearly Rs 70,000 crore Indian pharma market.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Triggering a full-blown patent fight with US-based Merck, domestic generic company Glenmark has launched a more affordable version of the multinational&#039;s blockbuster anti-diabetes drug Januvia. The move is expected to heighten tensions between MNCs and domestic generic companies which have been embroiled in patent disputes over the last couple of years.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Glenmark&#039;s launch could also throw up a different patent challenge for the regulators, which have seen two prominent cases where the compulsory licence route was used to launch life-saving drugs at just a fraction of the original price. &lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Glenmark has priced its diabetes drug around 30% cheaper than Merck&#039;s Januvia, and the savings to patients could be nearly Rs 5,000 a year.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Merck&#039;s diabetes therapies Januvia and Janumet, launched in the Indian market in 2008, are part of the &#039;gliptin&#039; family. The drugs together are nearly Rs 200-crore brands, making them one of the fastest growing medicines, and are ranked No. 2 in the oral diabetics market (according to IMS data).&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Confirming the move, a company official said, &amp;quot;Glenmark is a responsible company and has launched the products after due diligence and research. Like other branded generics, Glenmark&#039;s Zita &amp;amp; Zita-Met are also branded generics.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The &#039;gliptin&#039; market in India is estimated at around Rs 500 crore, growing at 25% per year. &#039;Gliptin&#039; is an oral once-a-day treatment option. Priced at Rs 43 per tablet, a month&#039;s dose of Merck&#039;s Januvia costs nearly Rs 1,300. Though &#039;gliptins&#039; have emerged as a good option in diabetes treatment, their use has been restricted largely because of their high prices, experts say.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;A MSD India official said; &amp;quot;We are disappointed in Glenmark&#039;s decision to introduce products that directly infringe upon our intellectual property. We believe our patents for Januvia and Janumet are valid and enforceable and will vigorously defend them. Strong intellectual property protection is essential for growing India&#039;s innovative capacity and economic growth. As an innovative pharmaceutical company, protection of our intellectual property is vital to ensuring that we continue to assume the tremendous monetary risks associated with the discovery of innovative medicines.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In India, where there are over 65 million people with type 2 diabetes, MSD also has a comprehensive strategy to help address the challenge of reducing disease burden and to increase access to our medicines, including India-specific responsible pricing for Januvia and Janumet, the official added.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;While Glenmark says that its product is &amp;quot;non-infringing&amp;quot; on Merck&#039;s drug, the details of Merck&#039;s patent on the drug sold in the market, were not available. Experts say that Glenmark&#039;s move will lead to a protracted legal battle with both sides sticking to their point.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Leena Menghaney, legal expert and campaign coordinator for Medicins Sans Frontieres, a medical humanitarian NGO, says &amp;quot;Access issues are also present in non-communicable lifestyle ailments. This becomes more relevant since developing countries are witnessing an increasing burden of non-communicable diseases, including heart disease, cancer, diabetes, and chronic obstructive pulmonary disease. Hence, generic companies have a big role to play to bring down prices of drugs used in these ailments.&amp;quot; &lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/patent-war-over-drugs-goes-chronic-rupali-mukherjee-20215.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Patent war over drugs goes chronic -Rupali Mukherjee | Im4change.org</title>
    <meta name="description" content="
-The Times of India



MUMBAI: Turf war between Big Pharma and generic companies, which was largely restricted to exorbitantly priced life-saving drugs for cancer and HIV, is now spilling over to other chronic ailments like diabetes, and threatening to change dynamics..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Patent war over drugs goes chronic -Rupali Mukherjee</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Times of India</div><p align="justify"><br /><em>MUMBAI: </em>Turf war between Big Pharma and generic companies, which was largely restricted to exorbitantly priced life-saving drugs for cancer and HIV, is now spilling over to other chronic ailments like diabetes, and threatening to change dynamics of the nearly Rs 70,000 crore Indian pharma market.</p><p align="justify">Triggering a full-blown patent fight with US-based Merck, domestic generic company Glenmark has launched a more affordable version of the multinational's blockbuster anti-diabetes drug Januvia. The move is expected to heighten tensions between MNCs and domestic generic companies which have been embroiled in patent disputes over the last couple of years.</p><p align="justify">Glenmark's launch could also throw up a different patent challenge for the regulators, which have seen two prominent cases where the compulsory licence route was used to launch life-saving drugs at just a fraction of the original price. </p><p align="justify">Glenmark has priced its diabetes drug around 30% cheaper than Merck's Januvia, and the savings to patients could be nearly Rs 5,000 a year.</p><p align="justify">Merck's diabetes therapies Januvia and Janumet, launched in the Indian market in 2008, are part of the 'gliptin' family. The drugs together are nearly Rs 200-crore brands, making them one of the fastest growing medicines, and are ranked No. 2 in the oral diabetics market (according to IMS data).</p><p align="justify">Confirming the move, a company official said, &quot;Glenmark is a responsible company and has launched the products after due diligence and research. Like other branded generics, Glenmark's Zita &amp; Zita-Met are also branded generics.&quot;</p><p align="justify">The 'gliptin' market in India is estimated at around Rs 500 crore, growing at 25% per year. 'Gliptin' is an oral once-a-day treatment option. Priced at Rs 43 per tablet, a month's dose of Merck's Januvia costs nearly Rs 1,300. Though 'gliptins' have emerged as a good option in diabetes treatment, their use has been restricted largely because of their high prices, experts say.</p><p align="justify">A MSD India official said; &quot;We are disappointed in Glenmark's decision to introduce products that directly infringe upon our intellectual property. We believe our patents for Januvia and Janumet are valid and enforceable and will vigorously defend them. Strong intellectual property protection is essential for growing India's innovative capacity and economic growth. As an innovative pharmaceutical company, protection of our intellectual property is vital to ensuring that we continue to assume the tremendous monetary risks associated with the discovery of innovative medicines.&quot;</p><p align="justify">In India, where there are over 65 million people with type 2 diabetes, MSD also has a comprehensive strategy to help address the challenge of reducing disease burden and to increase access to our medicines, including India-specific responsible pricing for Januvia and Janumet, the official added.</p><p align="justify">While Glenmark says that its product is &quot;non-infringing&quot; on Merck's drug, the details of Merck's patent on the drug sold in the market, were not available. Experts say that Glenmark's move will lead to a protracted legal battle with both sides sticking to their point.</p><p align="justify">Leena Menghaney, legal expert and campaign coordinator for Medicins Sans Frontieres, a medical humanitarian NGO, says &quot;Access issues are also present in non-communicable lifestyle ailments. This becomes more relevant since developing countries are witnessing an increasing burden of non-communicable diseases, including heart disease, cancer, diabetes, and chronic obstructive pulmonary disease. Hence, generic companies have a big role to play to bring down prices of drugs used in these ailments.&quot; </p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f5dc1ed9e80-trace').style.display = (document.getElementById('cakeErr67f5dc1ed9e80-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f5dc1ed9e80-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f5dc1ed9e80-code').style.display = (document.getElementById('cakeErr67f5dc1ed9e80-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f5dc1ed9e80-context').style.display = (document.getElementById('cakeErr67f5dc1ed9e80-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f5dc1ed9e80-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f5dc1ed9e80-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 20074,
		&#039;title&#039; =&gt; &#039;Patent war over drugs goes chronic -Rupali Mukherjee&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;MUMBAI: &lt;/em&gt;Turf war between Big Pharma and generic companies, which was largely restricted to exorbitantly priced life-saving drugs for cancer and HIV, is now spilling over to other chronic ailments like diabetes, and threatening to change dynamics of the nearly Rs 70,000 crore Indian pharma market.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Triggering a full-blown patent fight with US-based Merck, domestic generic company Glenmark has launched a more affordable version of the multinational&#039;s blockbuster anti-diabetes drug Januvia. The move is expected to heighten tensions between MNCs and domestic generic companies which have been embroiled in patent disputes over the last couple of years.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Glenmark&#039;s launch could also throw up a different patent challenge for the regulators, which have seen two prominent cases where the compulsory licence route was used to launch life-saving drugs at just a fraction of the original price. 
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Glenmark has priced its diabetes drug around 30% cheaper than Merck&#039;s Januvia, and the savings to patients could be nearly Rs 5,000 a year.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Merck&#039;s diabetes therapies Januvia and Janumet, launched in the Indian market in 2008, are part of the &#039;gliptin&#039; family. The drugs together are nearly Rs 200-crore brands, making them one of the fastest growing medicines, and are ranked No. 2 in the oral diabetics market (according to IMS data).
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Confirming the move, a company official said, &amp;quot;Glenmark is a responsible company and has launched the products after due diligence and research. Like other branded generics, Glenmark&#039;s Zita &amp;amp; Zita-Met are also branded generics.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The &#039;gliptin&#039; market in India is estimated at around Rs 500 crore, growing at 25% per year. &#039;Gliptin&#039; is an oral once-a-day treatment option. Priced at Rs 43 per tablet, a month&#039;s dose of Merck&#039;s Januvia costs nearly Rs 1,300. Though &#039;gliptins&#039; have emerged as a good option in diabetes treatment, their use has been restricted largely because of their high prices, experts say.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
A MSD India official said; &amp;quot;We are disappointed in Glenmark&#039;s decision to introduce products that directly infringe upon our intellectual property. We believe our patents for Januvia and Janumet are valid and enforceable and will vigorously defend them. Strong intellectual property protection is essential for growing India&#039;s innovative capacity and economic growth. As an innovative pharmaceutical company, protection of our intellectual property is vital to ensuring that we continue to assume the tremendous monetary risks associated with the discovery of innovative medicines.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In India, where there are over 65 million people with type 2 diabetes, MSD also has a comprehensive strategy to help address the challenge of reducing disease burden and to increase access to our medicines, including India-specific responsible pricing for Januvia and Janumet, the official added.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
While Glenmark says that its product is &amp;quot;non-infringing&amp;quot; on Merck&#039;s drug, the details of Merck&#039;s patent on the drug sold in the market, were not available. Experts say that Glenmark&#039;s move will lead to a protracted legal battle with both sides sticking to their point.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Leena Menghaney, legal expert and campaign coordinator for Medicins Sans Frontieres, a medical humanitarian NGO, says &amp;quot;Access issues are also present in non-communicable lifestyle ailments. This becomes more relevant since developing countries are witnessing an increasing burden of non-communicable diseases, including heart disease, cancer, diabetes, and chronic obstructive pulmonary disease. Hence, generic companies have a big role to play to bring down prices of drugs used in these ailments.&amp;quot; 
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Times of India, 1 April, 2013, http://timesofindia.indiatimes.com/business/india-business/Patent-war-over-drugs-goes-chronic/articleshow/19315419.cms&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;patent-war-over-drugs-goes-chronic-rupali-mukherjee-20215&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 20215,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 20074,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Patent war over drugs goes chronic -Rupali Mukherjee&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;diabetes,medicines,patents,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Times of India



MUMBAI: Turf war between Big Pharma and generic companies, which was largely restricted to exorbitantly priced life-saving drugs for cancer and HIV, is now spilling over to other chronic ailments like diabetes, and threatening to change dynamics...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;MUMBAI: &lt;/em&gt;Turf war between Big Pharma and generic companies, which was largely restricted to exorbitantly priced life-saving drugs for cancer and HIV, is now spilling over to other chronic ailments like diabetes, and threatening to change dynamics of the nearly Rs 70,000 crore Indian pharma market.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Triggering a full-blown patent fight with US-based Merck, domestic generic company Glenmark has launched a more affordable version of the multinational&#039;s blockbuster anti-diabetes drug Januvia. The move is expected to heighten tensions between MNCs and domestic generic companies which have been embroiled in patent disputes over the last couple of years.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Glenmark&#039;s launch could also throw up a different patent challenge for the regulators, which have seen two prominent cases where the compulsory licence route was used to launch life-saving drugs at just a fraction of the original price. &lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Glenmark has priced its diabetes drug around 30% cheaper than Merck&#039;s Januvia, and the savings to patients could be nearly Rs 5,000 a year.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Merck&#039;s diabetes therapies Januvia and Janumet, launched in the Indian market in 2008, are part of the &#039;gliptin&#039; family. The drugs together are nearly Rs 200-crore brands, making them one of the fastest growing medicines, and are ranked No. 2 in the oral diabetics market (according to IMS data).&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Confirming the move, a company official said, &amp;quot;Glenmark is a responsible company and has launched the products after due diligence and research. Like other branded generics, Glenmark&#039;s Zita &amp;amp; Zita-Met are also branded generics.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The &#039;gliptin&#039; market in India is estimated at around Rs 500 crore, growing at 25% per year. &#039;Gliptin&#039; is an oral once-a-day treatment option. Priced at Rs 43 per tablet, a month&#039;s dose of Merck&#039;s Januvia costs nearly Rs 1,300. Though &#039;gliptins&#039; have emerged as a good option in diabetes treatment, their use has been restricted largely because of their high prices, experts say.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;A MSD India official said; &amp;quot;We are disappointed in Glenmark&#039;s decision to introduce products that directly infringe upon our intellectual property. We believe our patents for Januvia and Janumet are valid and enforceable and will vigorously defend them. Strong intellectual property protection is essential for growing India&#039;s innovative capacity and economic growth. As an innovative pharmaceutical company, protection of our intellectual property is vital to ensuring that we continue to assume the tremendous monetary risks associated with the discovery of innovative medicines.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In India, where there are over 65 million people with type 2 diabetes, MSD also has a comprehensive strategy to help address the challenge of reducing disease burden and to increase access to our medicines, including India-specific responsible pricing for Januvia and Janumet, the official added.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;While Glenmark says that its product is &amp;quot;non-infringing&amp;quot; on Merck&#039;s drug, the details of Merck&#039;s patent on the drug sold in the market, were not available. Experts say that Glenmark&#039;s move will lead to a protracted legal battle with both sides sticking to their point.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Leena Menghaney, legal expert and campaign coordinator for Medicins Sans Frontieres, a medical humanitarian NGO, says &amp;quot;Access issues are also present in non-communicable lifestyle ailments. This becomes more relevant since developing countries are witnessing an increasing burden of non-communicable diseases, including heart disease, cancer, diabetes, and chronic obstructive pulmonary disease. Hence, generic companies have a big role to play to bring down prices of drugs used in these ailments.&amp;quot; &lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 20074,
	&#039;title&#039; =&gt; &#039;Patent war over drugs goes chronic -Rupali Mukherjee&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;MUMBAI: &lt;/em&gt;Turf war between Big Pharma and generic companies, which was largely restricted to exorbitantly priced life-saving drugs for cancer and HIV, is now spilling over to other chronic ailments like diabetes, and threatening to change dynamics of the nearly Rs 70,000 crore Indian pharma market.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Triggering a full-blown patent fight with US-based Merck, domestic generic company Glenmark has launched a more affordable version of the multinational&#039;s blockbuster anti-diabetes drug Januvia. The move is expected to heighten tensions between MNCs and domestic generic companies which have been embroiled in patent disputes over the last couple of years.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Glenmark&#039;s launch could also throw up a different patent challenge for the regulators, which have seen two prominent cases where the compulsory licence route was used to launch life-saving drugs at just a fraction of the original price. 
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Glenmark has priced its diabetes drug around 30% cheaper than Merck&#039;s Januvia, and the savings to patients could be nearly Rs 5,000 a year.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Merck&#039;s diabetes therapies Januvia and Janumet, launched in the Indian market in 2008, are part of the &#039;gliptin&#039; family. The drugs together are nearly Rs 200-crore brands, making them one of the fastest growing medicines, and are ranked No. 2 in the oral diabetics market (according to IMS data).
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Confirming the move, a company official said, &amp;quot;Glenmark is a responsible company and has launched the products after due diligence and research. Like other branded generics, Glenmark&#039;s Zita &amp;amp; Zita-Met are also branded generics.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The &#039;gliptin&#039; market in India is estimated at around Rs 500 crore, growing at 25% per year. &#039;Gliptin&#039; is an oral once-a-day treatment option. Priced at Rs 43 per tablet, a month&#039;s dose of Merck&#039;s Januvia costs nearly Rs 1,300. Though &#039;gliptins&#039; have emerged as a good option in diabetes treatment, their use has been restricted largely because of their high prices, experts say.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
A MSD India official said; &amp;quot;We are disappointed in Glenmark&#039;s decision to introduce products that directly infringe upon our intellectual property. We believe our patents for Januvia and Janumet are valid and enforceable and will vigorously defend them. Strong intellectual property protection is essential for growing India&#039;s innovative capacity and economic growth. As an innovative pharmaceutical company, protection of our intellectual property is vital to ensuring that we continue to assume the tremendous monetary risks associated with the discovery of innovative medicines.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In India, where there are over 65 million people with type 2 diabetes, MSD also has a comprehensive strategy to help address the challenge of reducing disease burden and to increase access to our medicines, including India-specific responsible pricing for Januvia and Janumet, the official added.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
While Glenmark says that its product is &amp;quot;non-infringing&amp;quot; on Merck&#039;s drug, the details of Merck&#039;s patent on the drug sold in the market, were not available. Experts say that Glenmark&#039;s move will lead to a protracted legal battle with both sides sticking to their point.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Leena Menghaney, legal expert and campaign coordinator for Medicins Sans Frontieres, a medical humanitarian NGO, says &amp;quot;Access issues are also present in non-communicable lifestyle ailments. This becomes more relevant since developing countries are witnessing an increasing burden of non-communicable diseases, including heart disease, cancer, diabetes, and chronic obstructive pulmonary disease. Hence, generic companies have a big role to play to bring down prices of drugs used in these ailments.&amp;quot; 
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Times of India, 1 April, 2013, http://timesofindia.indiatimes.com/business/india-business/Patent-war-over-drugs-goes-chronic/articleshow/19315419.cms&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;patent-war-over-drugs-goes-chronic-rupali-mukherjee-20215&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 20215,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 20074
$metaTitle = &#039;LATEST NEWS UPDATES | Patent war over drugs goes chronic -Rupali Mukherjee&#039;
$metaKeywords = &#039;diabetes,medicines,patents,Health&#039;
$metaDesc = &#039;
-The Times of India



MUMBAI: Turf war between Big Pharma and generic companies, which was largely restricted to exorbitantly priced life-saving drugs for cancer and HIV, is now spilling over to other chronic ailments like diabetes, and threatening to change dynamics...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;MUMBAI: &lt;/em&gt;Turf war between Big Pharma and generic companies, which was largely restricted to exorbitantly priced life-saving drugs for cancer and HIV, is now spilling over to other chronic ailments like diabetes, and threatening to change dynamics of the nearly Rs 70,000 crore Indian pharma market.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Triggering a full-blown patent fight with US-based Merck, domestic generic company Glenmark has launched a more affordable version of the multinational&#039;s blockbuster anti-diabetes drug Januvia. The move is expected to heighten tensions between MNCs and domestic generic companies which have been embroiled in patent disputes over the last couple of years.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Glenmark&#039;s launch could also throw up a different patent challenge for the regulators, which have seen two prominent cases where the compulsory licence route was used to launch life-saving drugs at just a fraction of the original price. &lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Glenmark has priced its diabetes drug around 30% cheaper than Merck&#039;s Januvia, and the savings to patients could be nearly Rs 5,000 a year.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Merck&#039;s diabetes therapies Januvia and Janumet, launched in the Indian market in 2008, are part of the &#039;gliptin&#039; family. The drugs together are nearly Rs 200-crore brands, making them one of the fastest growing medicines, and are ranked No. 2 in the oral diabetics market (according to IMS data).&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Confirming the move, a company official said, &amp;quot;Glenmark is a responsible company and has launched the products after due diligence and research. Like other branded generics, Glenmark&#039;s Zita &amp;amp; Zita-Met are also branded generics.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The &#039;gliptin&#039; market in India is estimated at around Rs 500 crore, growing at 25% per year. &#039;Gliptin&#039; is an oral once-a-day treatment option. Priced at Rs 43 per tablet, a month&#039;s dose of Merck&#039;s Januvia costs nearly Rs 1,300. Though &#039;gliptins&#039; have emerged as a good option in diabetes treatment, their use has been restricted largely because of their high prices, experts say.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;A MSD India official said; &amp;quot;We are disappointed in Glenmark&#039;s decision to introduce products that directly infringe upon our intellectual property. We believe our patents for Januvia and Janumet are valid and enforceable and will vigorously defend them. Strong intellectual property protection is essential for growing India&#039;s innovative capacity and economic growth. As an innovative pharmaceutical company, protection of our intellectual property is vital to ensuring that we continue to assume the tremendous monetary risks associated with the discovery of innovative medicines.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In India, where there are over 65 million people with type 2 diabetes, MSD also has a comprehensive strategy to help address the challenge of reducing disease burden and to increase access to our medicines, including India-specific responsible pricing for Januvia and Janumet, the official added.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;While Glenmark says that its product is &amp;quot;non-infringing&amp;quot; on Merck&#039;s drug, the details of Merck&#039;s patent on the drug sold in the market, were not available. Experts say that Glenmark&#039;s move will lead to a protracted legal battle with both sides sticking to their point.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Leena Menghaney, legal expert and campaign coordinator for Medicins Sans Frontieres, a medical humanitarian NGO, says &amp;quot;Access issues are also present in non-communicable lifestyle ailments. This becomes more relevant since developing countries are witnessing an increasing burden of non-communicable diseases, including heart disease, cancer, diabetes, and chronic obstructive pulmonary disease. Hence, generic companies have a big role to play to bring down prices of drugs used in these ailments.&amp;quot; &lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/patent-war-over-drugs-goes-chronic-rupali-mukherjee-20215.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Patent war over drugs goes chronic -Rupali Mukherjee | Im4change.org</title>
    <meta name="description" content="
-The Times of India



MUMBAI: Turf war between Big Pharma and generic companies, which was largely restricted to exorbitantly priced life-saving drugs for cancer and HIV, is now spilling over to other chronic ailments like diabetes, and threatening to change dynamics..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Patent war over drugs goes chronic -Rupali Mukherjee</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Times of India</div><p align="justify"><br /><em>MUMBAI: </em>Turf war between Big Pharma and generic companies, which was largely restricted to exorbitantly priced life-saving drugs for cancer and HIV, is now spilling over to other chronic ailments like diabetes, and threatening to change dynamics of the nearly Rs 70,000 crore Indian pharma market.</p><p align="justify">Triggering a full-blown patent fight with US-based Merck, domestic generic company Glenmark has launched a more affordable version of the multinational's blockbuster anti-diabetes drug Januvia. The move is expected to heighten tensions between MNCs and domestic generic companies which have been embroiled in patent disputes over the last couple of years.</p><p align="justify">Glenmark's launch could also throw up a different patent challenge for the regulators, which have seen two prominent cases where the compulsory licence route was used to launch life-saving drugs at just a fraction of the original price. </p><p align="justify">Glenmark has priced its diabetes drug around 30% cheaper than Merck's Januvia, and the savings to patients could be nearly Rs 5,000 a year.</p><p align="justify">Merck's diabetes therapies Januvia and Janumet, launched in the Indian market in 2008, are part of the 'gliptin' family. The drugs together are nearly Rs 200-crore brands, making them one of the fastest growing medicines, and are ranked No. 2 in the oral diabetics market (according to IMS data).</p><p align="justify">Confirming the move, a company official said, &quot;Glenmark is a responsible company and has launched the products after due diligence and research. Like other branded generics, Glenmark's Zita &amp; Zita-Met are also branded generics.&quot;</p><p align="justify">The 'gliptin' market in India is estimated at around Rs 500 crore, growing at 25% per year. 'Gliptin' is an oral once-a-day treatment option. Priced at Rs 43 per tablet, a month's dose of Merck's Januvia costs nearly Rs 1,300. Though 'gliptins' have emerged as a good option in diabetes treatment, their use has been restricted largely because of their high prices, experts say.</p><p align="justify">A MSD India official said; &quot;We are disappointed in Glenmark's decision to introduce products that directly infringe upon our intellectual property. We believe our patents for Januvia and Janumet are valid and enforceable and will vigorously defend them. Strong intellectual property protection is essential for growing India's innovative capacity and economic growth. As an innovative pharmaceutical company, protection of our intellectual property is vital to ensuring that we continue to assume the tremendous monetary risks associated with the discovery of innovative medicines.&quot;</p><p align="justify">In India, where there are over 65 million people with type 2 diabetes, MSD also has a comprehensive strategy to help address the challenge of reducing disease burden and to increase access to our medicines, including India-specific responsible pricing for Januvia and Janumet, the official added.</p><p align="justify">While Glenmark says that its product is &quot;non-infringing&quot; on Merck's drug, the details of Merck's patent on the drug sold in the market, were not available. Experts say that Glenmark's move will lead to a protracted legal battle with both sides sticking to their point.</p><p align="justify">Leena Menghaney, legal expert and campaign coordinator for Medicins Sans Frontieres, a medical humanitarian NGO, says &quot;Access issues are also present in non-communicable lifestyle ailments. This becomes more relevant since developing countries are witnessing an increasing burden of non-communicable diseases, including heart disease, cancer, diabetes, and chronic obstructive pulmonary disease. Hence, generic companies have a big role to play to bring down prices of drugs used in these ailments.&quot; </p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f5dc1ed9e80-trace').style.display = (document.getElementById('cakeErr67f5dc1ed9e80-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f5dc1ed9e80-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f5dc1ed9e80-code').style.display = (document.getElementById('cakeErr67f5dc1ed9e80-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f5dc1ed9e80-context').style.display = (document.getElementById('cakeErr67f5dc1ed9e80-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f5dc1ed9e80-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f5dc1ed9e80-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 20074,
		&#039;title&#039; =&gt; &#039;Patent war over drugs goes chronic -Rupali Mukherjee&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;MUMBAI: &lt;/em&gt;Turf war between Big Pharma and generic companies, which was largely restricted to exorbitantly priced life-saving drugs for cancer and HIV, is now spilling over to other chronic ailments like diabetes, and threatening to change dynamics of the nearly Rs 70,000 crore Indian pharma market.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Triggering a full-blown patent fight with US-based Merck, domestic generic company Glenmark has launched a more affordable version of the multinational&#039;s blockbuster anti-diabetes drug Januvia. The move is expected to heighten tensions between MNCs and domestic generic companies which have been embroiled in patent disputes over the last couple of years.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Glenmark&#039;s launch could also throw up a different patent challenge for the regulators, which have seen two prominent cases where the compulsory licence route was used to launch life-saving drugs at just a fraction of the original price. 
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Glenmark has priced its diabetes drug around 30% cheaper than Merck&#039;s Januvia, and the savings to patients could be nearly Rs 5,000 a year.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Merck&#039;s diabetes therapies Januvia and Janumet, launched in the Indian market in 2008, are part of the &#039;gliptin&#039; family. The drugs together are nearly Rs 200-crore brands, making them one of the fastest growing medicines, and are ranked No. 2 in the oral diabetics market (according to IMS data).
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Confirming the move, a company official said, &amp;quot;Glenmark is a responsible company and has launched the products after due diligence and research. Like other branded generics, Glenmark&#039;s Zita &amp;amp; Zita-Met are also branded generics.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The &#039;gliptin&#039; market in India is estimated at around Rs 500 crore, growing at 25% per year. &#039;Gliptin&#039; is an oral once-a-day treatment option. Priced at Rs 43 per tablet, a month&#039;s dose of Merck&#039;s Januvia costs nearly Rs 1,300. Though &#039;gliptins&#039; have emerged as a good option in diabetes treatment, their use has been restricted largely because of their high prices, experts say.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
A MSD India official said; &amp;quot;We are disappointed in Glenmark&#039;s decision to introduce products that directly infringe upon our intellectual property. We believe our patents for Januvia and Janumet are valid and enforceable and will vigorously defend them. Strong intellectual property protection is essential for growing India&#039;s innovative capacity and economic growth. As an innovative pharmaceutical company, protection of our intellectual property is vital to ensuring that we continue to assume the tremendous monetary risks associated with the discovery of innovative medicines.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In India, where there are over 65 million people with type 2 diabetes, MSD also has a comprehensive strategy to help address the challenge of reducing disease burden and to increase access to our medicines, including India-specific responsible pricing for Januvia and Janumet, the official added.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
While Glenmark says that its product is &amp;quot;non-infringing&amp;quot; on Merck&#039;s drug, the details of Merck&#039;s patent on the drug sold in the market, were not available. Experts say that Glenmark&#039;s move will lead to a protracted legal battle with both sides sticking to their point.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Leena Menghaney, legal expert and campaign coordinator for Medicins Sans Frontieres, a medical humanitarian NGO, says &amp;quot;Access issues are also present in non-communicable lifestyle ailments. This becomes more relevant since developing countries are witnessing an increasing burden of non-communicable diseases, including heart disease, cancer, diabetes, and chronic obstructive pulmonary disease. Hence, generic companies have a big role to play to bring down prices of drugs used in these ailments.&amp;quot; 
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Times of India, 1 April, 2013, http://timesofindia.indiatimes.com/business/india-business/Patent-war-over-drugs-goes-chronic/articleshow/19315419.cms&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;patent-war-over-drugs-goes-chronic-rupali-mukherjee-20215&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 20215,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 20074,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Patent war over drugs goes chronic -Rupali Mukherjee&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;diabetes,medicines,patents,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Times of India



MUMBAI: Turf war between Big Pharma and generic companies, which was largely restricted to exorbitantly priced life-saving drugs for cancer and HIV, is now spilling over to other chronic ailments like diabetes, and threatening to change dynamics...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;MUMBAI: &lt;/em&gt;Turf war between Big Pharma and generic companies, which was largely restricted to exorbitantly priced life-saving drugs for cancer and HIV, is now spilling over to other chronic ailments like diabetes, and threatening to change dynamics of the nearly Rs 70,000 crore Indian pharma market.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Triggering a full-blown patent fight with US-based Merck, domestic generic company Glenmark has launched a more affordable version of the multinational&#039;s blockbuster anti-diabetes drug Januvia. The move is expected to heighten tensions between MNCs and domestic generic companies which have been embroiled in patent disputes over the last couple of years.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Glenmark&#039;s launch could also throw up a different patent challenge for the regulators, which have seen two prominent cases where the compulsory licence route was used to launch life-saving drugs at just a fraction of the original price. &lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Glenmark has priced its diabetes drug around 30% cheaper than Merck&#039;s Januvia, and the savings to patients could be nearly Rs 5,000 a year.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Merck&#039;s diabetes therapies Januvia and Janumet, launched in the Indian market in 2008, are part of the &#039;gliptin&#039; family. The drugs together are nearly Rs 200-crore brands, making them one of the fastest growing medicines, and are ranked No. 2 in the oral diabetics market (according to IMS data).&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Confirming the move, a company official said, &amp;quot;Glenmark is a responsible company and has launched the products after due diligence and research. Like other branded generics, Glenmark&#039;s Zita &amp;amp; Zita-Met are also branded generics.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The &#039;gliptin&#039; market in India is estimated at around Rs 500 crore, growing at 25% per year. &#039;Gliptin&#039; is an oral once-a-day treatment option. Priced at Rs 43 per tablet, a month&#039;s dose of Merck&#039;s Januvia costs nearly Rs 1,300. Though &#039;gliptins&#039; have emerged as a good option in diabetes treatment, their use has been restricted largely because of their high prices, experts say.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;A MSD India official said; &amp;quot;We are disappointed in Glenmark&#039;s decision to introduce products that directly infringe upon our intellectual property. We believe our patents for Januvia and Janumet are valid and enforceable and will vigorously defend them. Strong intellectual property protection is essential for growing India&#039;s innovative capacity and economic growth. As an innovative pharmaceutical company, protection of our intellectual property is vital to ensuring that we continue to assume the tremendous monetary risks associated with the discovery of innovative medicines.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In India, where there are over 65 million people with type 2 diabetes, MSD also has a comprehensive strategy to help address the challenge of reducing disease burden and to increase access to our medicines, including India-specific responsible pricing for Januvia and Janumet, the official added.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;While Glenmark says that its product is &amp;quot;non-infringing&amp;quot; on Merck&#039;s drug, the details of Merck&#039;s patent on the drug sold in the market, were not available. Experts say that Glenmark&#039;s move will lead to a protracted legal battle with both sides sticking to their point.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Leena Menghaney, legal expert and campaign coordinator for Medicins Sans Frontieres, a medical humanitarian NGO, says &amp;quot;Access issues are also present in non-communicable lifestyle ailments. This becomes more relevant since developing countries are witnessing an increasing burden of non-communicable diseases, including heart disease, cancer, diabetes, and chronic obstructive pulmonary disease. Hence, generic companies have a big role to play to bring down prices of drugs used in these ailments.&amp;quot; &lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 20074,
	&#039;title&#039; =&gt; &#039;Patent war over drugs goes chronic -Rupali Mukherjee&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;MUMBAI: &lt;/em&gt;Turf war between Big Pharma and generic companies, which was largely restricted to exorbitantly priced life-saving drugs for cancer and HIV, is now spilling over to other chronic ailments like diabetes, and threatening to change dynamics of the nearly Rs 70,000 crore Indian pharma market.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Triggering a full-blown patent fight with US-based Merck, domestic generic company Glenmark has launched a more affordable version of the multinational&#039;s blockbuster anti-diabetes drug Januvia. The move is expected to heighten tensions between MNCs and domestic generic companies which have been embroiled in patent disputes over the last couple of years.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Glenmark&#039;s launch could also throw up a different patent challenge for the regulators, which have seen two prominent cases where the compulsory licence route was used to launch life-saving drugs at just a fraction of the original price. 
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Glenmark has priced its diabetes drug around 30% cheaper than Merck&#039;s Januvia, and the savings to patients could be nearly Rs 5,000 a year.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Merck&#039;s diabetes therapies Januvia and Janumet, launched in the Indian market in 2008, are part of the &#039;gliptin&#039; family. The drugs together are nearly Rs 200-crore brands, making them one of the fastest growing medicines, and are ranked No. 2 in the oral diabetics market (according to IMS data).
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Confirming the move, a company official said, &amp;quot;Glenmark is a responsible company and has launched the products after due diligence and research. Like other branded generics, Glenmark&#039;s Zita &amp;amp; Zita-Met are also branded generics.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The &#039;gliptin&#039; market in India is estimated at around Rs 500 crore, growing at 25% per year. &#039;Gliptin&#039; is an oral once-a-day treatment option. Priced at Rs 43 per tablet, a month&#039;s dose of Merck&#039;s Januvia costs nearly Rs 1,300. Though &#039;gliptins&#039; have emerged as a good option in diabetes treatment, their use has been restricted largely because of their high prices, experts say.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
A MSD India official said; &amp;quot;We are disappointed in Glenmark&#039;s decision to introduce products that directly infringe upon our intellectual property. We believe our patents for Januvia and Janumet are valid and enforceable and will vigorously defend them. Strong intellectual property protection is essential for growing India&#039;s innovative capacity and economic growth. As an innovative pharmaceutical company, protection of our intellectual property is vital to ensuring that we continue to assume the tremendous monetary risks associated with the discovery of innovative medicines.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In India, where there are over 65 million people with type 2 diabetes, MSD also has a comprehensive strategy to help address the challenge of reducing disease burden and to increase access to our medicines, including India-specific responsible pricing for Januvia and Janumet, the official added.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
While Glenmark says that its product is &amp;quot;non-infringing&amp;quot; on Merck&#039;s drug, the details of Merck&#039;s patent on the drug sold in the market, were not available. Experts say that Glenmark&#039;s move will lead to a protracted legal battle with both sides sticking to their point.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Leena Menghaney, legal expert and campaign coordinator for Medicins Sans Frontieres, a medical humanitarian NGO, says &amp;quot;Access issues are also present in non-communicable lifestyle ailments. This becomes more relevant since developing countries are witnessing an increasing burden of non-communicable diseases, including heart disease, cancer, diabetes, and chronic obstructive pulmonary disease. Hence, generic companies have a big role to play to bring down prices of drugs used in these ailments.&amp;quot; 
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Times of India, 1 April, 2013, http://timesofindia.indiatimes.com/business/india-business/Patent-war-over-drugs-goes-chronic/articleshow/19315419.cms&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;patent-war-over-drugs-goes-chronic-rupali-mukherjee-20215&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 20215,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 20074
$metaTitle = &#039;LATEST NEWS UPDATES | Patent war over drugs goes chronic -Rupali Mukherjee&#039;
$metaKeywords = &#039;diabetes,medicines,patents,Health&#039;
$metaDesc = &#039;
-The Times of India



MUMBAI: Turf war between Big Pharma and generic companies, which was largely restricted to exorbitantly priced life-saving drugs for cancer and HIV, is now spilling over to other chronic ailments like diabetes, and threatening to change dynamics...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;MUMBAI: &lt;/em&gt;Turf war between Big Pharma and generic companies, which was largely restricted to exorbitantly priced life-saving drugs for cancer and HIV, is now spilling over to other chronic ailments like diabetes, and threatening to change dynamics of the nearly Rs 70,000 crore Indian pharma market.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Triggering a full-blown patent fight with US-based Merck, domestic generic company Glenmark has launched a more affordable version of the multinational&#039;s blockbuster anti-diabetes drug Januvia. The move is expected to heighten tensions between MNCs and domestic generic companies which have been embroiled in patent disputes over the last couple of years.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Glenmark&#039;s launch could also throw up a different patent challenge for the regulators, which have seen two prominent cases where the compulsory licence route was used to launch life-saving drugs at just a fraction of the original price. &lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Glenmark has priced its diabetes drug around 30% cheaper than Merck&#039;s Januvia, and the savings to patients could be nearly Rs 5,000 a year.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Merck&#039;s diabetes therapies Januvia and Janumet, launched in the Indian market in 2008, are part of the &#039;gliptin&#039; family. The drugs together are nearly Rs 200-crore brands, making them one of the fastest growing medicines, and are ranked No. 2 in the oral diabetics market (according to IMS data).&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Confirming the move, a company official said, &amp;quot;Glenmark is a responsible company and has launched the products after due diligence and research. Like other branded generics, Glenmark&#039;s Zita &amp;amp; Zita-Met are also branded generics.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The &#039;gliptin&#039; market in India is estimated at around Rs 500 crore, growing at 25% per year. &#039;Gliptin&#039; is an oral once-a-day treatment option. Priced at Rs 43 per tablet, a month&#039;s dose of Merck&#039;s Januvia costs nearly Rs 1,300. Though &#039;gliptins&#039; have emerged as a good option in diabetes treatment, their use has been restricted largely because of their high prices, experts say.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;A MSD India official said; &amp;quot;We are disappointed in Glenmark&#039;s decision to introduce products that directly infringe upon our intellectual property. We believe our patents for Januvia and Janumet are valid and enforceable and will vigorously defend them. Strong intellectual property protection is essential for growing India&#039;s innovative capacity and economic growth. As an innovative pharmaceutical company, protection of our intellectual property is vital to ensuring that we continue to assume the tremendous monetary risks associated with the discovery of innovative medicines.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In India, where there are over 65 million people with type 2 diabetes, MSD also has a comprehensive strategy to help address the challenge of reducing disease burden and to increase access to our medicines, including India-specific responsible pricing for Januvia and Janumet, the official added.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;While Glenmark says that its product is &amp;quot;non-infringing&amp;quot; on Merck&#039;s drug, the details of Merck&#039;s patent on the drug sold in the market, were not available. Experts say that Glenmark&#039;s move will lead to a protracted legal battle with both sides sticking to their point.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Leena Menghaney, legal expert and campaign coordinator for Medicins Sans Frontieres, a medical humanitarian NGO, says &amp;quot;Access issues are also present in non-communicable lifestyle ailments. This becomes more relevant since developing countries are witnessing an increasing burden of non-communicable diseases, including heart disease, cancer, diabetes, and chronic obstructive pulmonary disease. Hence, generic companies have a big role to play to bring down prices of drugs used in these ailments.&amp;quot; &lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/patent-war-over-drugs-goes-chronic-rupali-mukherjee-20215.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Patent war over drugs goes chronic -Rupali Mukherjee | Im4change.org</title>
    <meta name="description" content="
-The Times of India



MUMBAI: Turf war between Big Pharma and generic companies, which was largely restricted to exorbitantly priced life-saving drugs for cancer and HIV, is now spilling over to other chronic ailments like diabetes, and threatening to change dynamics..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Patent war over drugs goes chronic -Rupali Mukherjee</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Times of India</div><p align="justify"><br /><em>MUMBAI: </em>Turf war between Big Pharma and generic companies, which was largely restricted to exorbitantly priced life-saving drugs for cancer and HIV, is now spilling over to other chronic ailments like diabetes, and threatening to change dynamics of the nearly Rs 70,000 crore Indian pharma market.</p><p align="justify">Triggering a full-blown patent fight with US-based Merck, domestic generic company Glenmark has launched a more affordable version of the multinational's blockbuster anti-diabetes drug Januvia. The move is expected to heighten tensions between MNCs and domestic generic companies which have been embroiled in patent disputes over the last couple of years.</p><p align="justify">Glenmark's launch could also throw up a different patent challenge for the regulators, which have seen two prominent cases where the compulsory licence route was used to launch life-saving drugs at just a fraction of the original price. </p><p align="justify">Glenmark has priced its diabetes drug around 30% cheaper than Merck's Januvia, and the savings to patients could be nearly Rs 5,000 a year.</p><p align="justify">Merck's diabetes therapies Januvia and Janumet, launched in the Indian market in 2008, are part of the 'gliptin' family. The drugs together are nearly Rs 200-crore brands, making them one of the fastest growing medicines, and are ranked No. 2 in the oral diabetics market (according to IMS data).</p><p align="justify">Confirming the move, a company official said, &quot;Glenmark is a responsible company and has launched the products after due diligence and research. Like other branded generics, Glenmark's Zita &amp; Zita-Met are also branded generics.&quot;</p><p align="justify">The 'gliptin' market in India is estimated at around Rs 500 crore, growing at 25% per year. 'Gliptin' is an oral once-a-day treatment option. Priced at Rs 43 per tablet, a month's dose of Merck's Januvia costs nearly Rs 1,300. Though 'gliptins' have emerged as a good option in diabetes treatment, their use has been restricted largely because of their high prices, experts say.</p><p align="justify">A MSD India official said; &quot;We are disappointed in Glenmark's decision to introduce products that directly infringe upon our intellectual property. We believe our patents for Januvia and Janumet are valid and enforceable and will vigorously defend them. Strong intellectual property protection is essential for growing India's innovative capacity and economic growth. As an innovative pharmaceutical company, protection of our intellectual property is vital to ensuring that we continue to assume the tremendous monetary risks associated with the discovery of innovative medicines.&quot;</p><p align="justify">In India, where there are over 65 million people with type 2 diabetes, MSD also has a comprehensive strategy to help address the challenge of reducing disease burden and to increase access to our medicines, including India-specific responsible pricing for Januvia and Janumet, the official added.</p><p align="justify">While Glenmark says that its product is &quot;non-infringing&quot; on Merck's drug, the details of Merck's patent on the drug sold in the market, were not available. Experts say that Glenmark's move will lead to a protracted legal battle with both sides sticking to their point.</p><p align="justify">Leena Menghaney, legal expert and campaign coordinator for Medicins Sans Frontieres, a medical humanitarian NGO, says &quot;Access issues are also present in non-communicable lifestyle ailments. This becomes more relevant since developing countries are witnessing an increasing burden of non-communicable diseases, including heart disease, cancer, diabetes, and chronic obstructive pulmonary disease. Hence, generic companies have a big role to play to bring down prices of drugs used in these ailments.&quot; </p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 20074,
		'title' => 'Patent war over drugs goes chronic -Rupali Mukherjee',
		'subheading' => '',
		'description' => '<div align="justify">
-The Times of India
</div>
<p align="justify">
<br />
<em>MUMBAI: </em>Turf war between Big Pharma and generic companies, which was largely restricted to exorbitantly priced life-saving drugs for cancer and HIV, is now spilling over to other chronic ailments like diabetes, and threatening to change dynamics of the nearly Rs 70,000 crore Indian pharma market.
</p>
<p align="justify">
Triggering a full-blown patent fight with US-based Merck, domestic generic company Glenmark has launched a more affordable version of the multinational's blockbuster anti-diabetes drug Januvia. The move is expected to heighten tensions between MNCs and domestic generic companies which have been embroiled in patent disputes over the last couple of years.
</p>
<p align="justify">
Glenmark's launch could also throw up a different patent challenge for the regulators, which have seen two prominent cases where the compulsory licence route was used to launch life-saving drugs at just a fraction of the original price. 
</p>
<p align="justify">
Glenmark has priced its diabetes drug around 30% cheaper than Merck's Januvia, and the savings to patients could be nearly Rs 5,000 a year.
</p>
<p align="justify">
Merck's diabetes therapies Januvia and Janumet, launched in the Indian market in 2008, are part of the 'gliptin' family. The drugs together are nearly Rs 200-crore brands, making them one of the fastest growing medicines, and are ranked No. 2 in the oral diabetics market (according to IMS data).
</p>
<p align="justify">
Confirming the move, a company official said, &quot;Glenmark is a responsible company and has launched the products after due diligence and research. Like other branded generics, Glenmark's Zita &amp; Zita-Met are also branded generics.&quot;
</p>
<p align="justify">
The 'gliptin' market in India is estimated at around Rs 500 crore, growing at 25% per year. 'Gliptin' is an oral once-a-day treatment option. Priced at Rs 43 per tablet, a month's dose of Merck's Januvia costs nearly Rs 1,300. Though 'gliptins' have emerged as a good option in diabetes treatment, their use has been restricted largely because of their high prices, experts say.
</p>
<p align="justify">
A MSD India official said; &quot;We are disappointed in Glenmark's decision to introduce products that directly infringe upon our intellectual property. We believe our patents for Januvia and Janumet are valid and enforceable and will vigorously defend them. Strong intellectual property protection is essential for growing India's innovative capacity and economic growth. As an innovative pharmaceutical company, protection of our intellectual property is vital to ensuring that we continue to assume the tremendous monetary risks associated with the discovery of innovative medicines.&quot;
</p>
<p align="justify">
In India, where there are over 65 million people with type 2 diabetes, MSD also has a comprehensive strategy to help address the challenge of reducing disease burden and to increase access to our medicines, including India-specific responsible pricing for Januvia and Janumet, the official added.
</p>
<p align="justify">
While Glenmark says that its product is &quot;non-infringing&quot; on Merck's drug, the details of Merck's patent on the drug sold in the market, were not available. Experts say that Glenmark's move will lead to a protracted legal battle with both sides sticking to their point.
</p>
<p align="justify">
Leena Menghaney, legal expert and campaign coordinator for Medicins Sans Frontieres, a medical humanitarian NGO, says &quot;Access issues are also present in non-communicable lifestyle ailments. This becomes more relevant since developing countries are witnessing an increasing burden of non-communicable diseases, including heart disease, cancer, diabetes, and chronic obstructive pulmonary disease. Hence, generic companies have a big role to play to bring down prices of drugs used in these ailments.&quot; 
</p>',
		'credit_writer' => 'The Times of India, 1 April, 2013, http://timesofindia.indiatimes.com/business/india-business/Patent-war-over-drugs-goes-chronic/articleshow/19315419.cms',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'patent-war-over-drugs-goes-chronic-rupali-mukherjee-20215',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 20215,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 20074,
	'metaTitle' => 'LATEST NEWS UPDATES | Patent war over drugs goes chronic -Rupali Mukherjee',
	'metaKeywords' => 'diabetes,medicines,patents,Health',
	'metaDesc' => '
-The Times of India



MUMBAI: Turf war between Big Pharma and generic companies, which was largely restricted to exorbitantly priced life-saving drugs for cancer and HIV, is now spilling over to other chronic ailments like diabetes, and threatening to change dynamics...',
	'disp' => '<div align="justify">-The Times of India</div><p align="justify"><br /><em>MUMBAI: </em>Turf war between Big Pharma and generic companies, which was largely restricted to exorbitantly priced life-saving drugs for cancer and HIV, is now spilling over to other chronic ailments like diabetes, and threatening to change dynamics of the nearly Rs 70,000 crore Indian pharma market.</p><p align="justify">Triggering a full-blown patent fight with US-based Merck, domestic generic company Glenmark has launched a more affordable version of the multinational's blockbuster anti-diabetes drug Januvia. The move is expected to heighten tensions between MNCs and domestic generic companies which have been embroiled in patent disputes over the last couple of years.</p><p align="justify">Glenmark's launch could also throw up a different patent challenge for the regulators, which have seen two prominent cases where the compulsory licence route was used to launch life-saving drugs at just a fraction of the original price. </p><p align="justify">Glenmark has priced its diabetes drug around 30% cheaper than Merck's Januvia, and the savings to patients could be nearly Rs 5,000 a year.</p><p align="justify">Merck's diabetes therapies Januvia and Janumet, launched in the Indian market in 2008, are part of the 'gliptin' family. The drugs together are nearly Rs 200-crore brands, making them one of the fastest growing medicines, and are ranked No. 2 in the oral diabetics market (according to IMS data).</p><p align="justify">Confirming the move, a company official said, &quot;Glenmark is a responsible company and has launched the products after due diligence and research. Like other branded generics, Glenmark's Zita &amp; Zita-Met are also branded generics.&quot;</p><p align="justify">The 'gliptin' market in India is estimated at around Rs 500 crore, growing at 25% per year. 'Gliptin' is an oral once-a-day treatment option. Priced at Rs 43 per tablet, a month's dose of Merck's Januvia costs nearly Rs 1,300. Though 'gliptins' have emerged as a good option in diabetes treatment, their use has been restricted largely because of their high prices, experts say.</p><p align="justify">A MSD India official said; &quot;We are disappointed in Glenmark's decision to introduce products that directly infringe upon our intellectual property. We believe our patents for Januvia and Janumet are valid and enforceable and will vigorously defend them. Strong intellectual property protection is essential for growing India's innovative capacity and economic growth. As an innovative pharmaceutical company, protection of our intellectual property is vital to ensuring that we continue to assume the tremendous monetary risks associated with the discovery of innovative medicines.&quot;</p><p align="justify">In India, where there are over 65 million people with type 2 diabetes, MSD also has a comprehensive strategy to help address the challenge of reducing disease burden and to increase access to our medicines, including India-specific responsible pricing for Januvia and Janumet, the official added.</p><p align="justify">While Glenmark says that its product is &quot;non-infringing&quot; on Merck's drug, the details of Merck's patent on the drug sold in the market, were not available. Experts say that Glenmark's move will lead to a protracted legal battle with both sides sticking to their point.</p><p align="justify">Leena Menghaney, legal expert and campaign coordinator for Medicins Sans Frontieres, a medical humanitarian NGO, says &quot;Access issues are also present in non-communicable lifestyle ailments. This becomes more relevant since developing countries are witnessing an increasing burden of non-communicable diseases, including heart disease, cancer, diabetes, and chronic obstructive pulmonary disease. Hence, generic companies have a big role to play to bring down prices of drugs used in these ailments.&quot; </p>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 20074,
	'title' => 'Patent war over drugs goes chronic -Rupali Mukherjee',
	'subheading' => '',
	'description' => '<div align="justify">
-The Times of India
</div>
<p align="justify">
<br />
<em>MUMBAI: </em>Turf war between Big Pharma and generic companies, which was largely restricted to exorbitantly priced life-saving drugs for cancer and HIV, is now spilling over to other chronic ailments like diabetes, and threatening to change dynamics of the nearly Rs 70,000 crore Indian pharma market.
</p>
<p align="justify">
Triggering a full-blown patent fight with US-based Merck, domestic generic company Glenmark has launched a more affordable version of the multinational's blockbuster anti-diabetes drug Januvia. The move is expected to heighten tensions between MNCs and domestic generic companies which have been embroiled in patent disputes over the last couple of years.
</p>
<p align="justify">
Glenmark's launch could also throw up a different patent challenge for the regulators, which have seen two prominent cases where the compulsory licence route was used to launch life-saving drugs at just a fraction of the original price. 
</p>
<p align="justify">
Glenmark has priced its diabetes drug around 30% cheaper than Merck's Januvia, and the savings to patients could be nearly Rs 5,000 a year.
</p>
<p align="justify">
Merck's diabetes therapies Januvia and Janumet, launched in the Indian market in 2008, are part of the 'gliptin' family. The drugs together are nearly Rs 200-crore brands, making them one of the fastest growing medicines, and are ranked No. 2 in the oral diabetics market (according to IMS data).
</p>
<p align="justify">
Confirming the move, a company official said, &quot;Glenmark is a responsible company and has launched the products after due diligence and research. Like other branded generics, Glenmark's Zita &amp; Zita-Met are also branded generics.&quot;
</p>
<p align="justify">
The 'gliptin' market in India is estimated at around Rs 500 crore, growing at 25% per year. 'Gliptin' is an oral once-a-day treatment option. Priced at Rs 43 per tablet, a month's dose of Merck's Januvia costs nearly Rs 1,300. Though 'gliptins' have emerged as a good option in diabetes treatment, their use has been restricted largely because of their high prices, experts say.
</p>
<p align="justify">
A MSD India official said; &quot;We are disappointed in Glenmark's decision to introduce products that directly infringe upon our intellectual property. We believe our patents for Januvia and Janumet are valid and enforceable and will vigorously defend them. Strong intellectual property protection is essential for growing India's innovative capacity and economic growth. As an innovative pharmaceutical company, protection of our intellectual property is vital to ensuring that we continue to assume the tremendous monetary risks associated with the discovery of innovative medicines.&quot;
</p>
<p align="justify">
In India, where there are over 65 million people with type 2 diabetes, MSD also has a comprehensive strategy to help address the challenge of reducing disease burden and to increase access to our medicines, including India-specific responsible pricing for Januvia and Janumet, the official added.
</p>
<p align="justify">
While Glenmark says that its product is &quot;non-infringing&quot; on Merck's drug, the details of Merck's patent on the drug sold in the market, were not available. Experts say that Glenmark's move will lead to a protracted legal battle with both sides sticking to their point.
</p>
<p align="justify">
Leena Menghaney, legal expert and campaign coordinator for Medicins Sans Frontieres, a medical humanitarian NGO, says &quot;Access issues are also present in non-communicable lifestyle ailments. This becomes more relevant since developing countries are witnessing an increasing burden of non-communicable diseases, including heart disease, cancer, diabetes, and chronic obstructive pulmonary disease. Hence, generic companies have a big role to play to bring down prices of drugs used in these ailments.&quot; 
</p>',
	'credit_writer' => 'The Times of India, 1 April, 2013, http://timesofindia.indiatimes.com/business/india-business/Patent-war-over-drugs-goes-chronic/articleshow/19315419.cms',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'patent-war-over-drugs-goes-chronic-rupali-mukherjee-20215',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 20215,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {},
		(int) 2 => object(Cake\ORM\Entity) {},
		(int) 3 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 20074
$metaTitle = 'LATEST NEWS UPDATES | Patent war over drugs goes chronic -Rupali Mukherjee'
$metaKeywords = 'diabetes,medicines,patents,Health'
$metaDesc = '
-The Times of India



MUMBAI: Turf war between Big Pharma and generic companies, which was largely restricted to exorbitantly priced life-saving drugs for cancer and HIV, is now spilling over to other chronic ailments like diabetes, and threatening to change dynamics...'
$disp = '<div align="justify">-The Times of India</div><p align="justify"><br /><em>MUMBAI: </em>Turf war between Big Pharma and generic companies, which was largely restricted to exorbitantly priced life-saving drugs for cancer and HIV, is now spilling over to other chronic ailments like diabetes, and threatening to change dynamics of the nearly Rs 70,000 crore Indian pharma market.</p><p align="justify">Triggering a full-blown patent fight with US-based Merck, domestic generic company Glenmark has launched a more affordable version of the multinational's blockbuster anti-diabetes drug Januvia. The move is expected to heighten tensions between MNCs and domestic generic companies which have been embroiled in patent disputes over the last couple of years.</p><p align="justify">Glenmark's launch could also throw up a different patent challenge for the regulators, which have seen two prominent cases where the compulsory licence route was used to launch life-saving drugs at just a fraction of the original price. </p><p align="justify">Glenmark has priced its diabetes drug around 30% cheaper than Merck's Januvia, and the savings to patients could be nearly Rs 5,000 a year.</p><p align="justify">Merck's diabetes therapies Januvia and Janumet, launched in the Indian market in 2008, are part of the 'gliptin' family. The drugs together are nearly Rs 200-crore brands, making them one of the fastest growing medicines, and are ranked No. 2 in the oral diabetics market (according to IMS data).</p><p align="justify">Confirming the move, a company official said, &quot;Glenmark is a responsible company and has launched the products after due diligence and research. Like other branded generics, Glenmark's Zita &amp; Zita-Met are also branded generics.&quot;</p><p align="justify">The 'gliptin' market in India is estimated at around Rs 500 crore, growing at 25% per year. 'Gliptin' is an oral once-a-day treatment option. Priced at Rs 43 per tablet, a month's dose of Merck's Januvia costs nearly Rs 1,300. Though 'gliptins' have emerged as a good option in diabetes treatment, their use has been restricted largely because of their high prices, experts say.</p><p align="justify">A MSD India official said; &quot;We are disappointed in Glenmark's decision to introduce products that directly infringe upon our intellectual property. We believe our patents for Januvia and Janumet are valid and enforceable and will vigorously defend them. Strong intellectual property protection is essential for growing India's innovative capacity and economic growth. As an innovative pharmaceutical company, protection of our intellectual property is vital to ensuring that we continue to assume the tremendous monetary risks associated with the discovery of innovative medicines.&quot;</p><p align="justify">In India, where there are over 65 million people with type 2 diabetes, MSD also has a comprehensive strategy to help address the challenge of reducing disease burden and to increase access to our medicines, including India-specific responsible pricing for Januvia and Janumet, the official added.</p><p align="justify">While Glenmark says that its product is &quot;non-infringing&quot; on Merck's drug, the details of Merck's patent on the drug sold in the market, were not available. Experts say that Glenmark's move will lead to a protracted legal battle with both sides sticking to their point.</p><p align="justify">Leena Menghaney, legal expert and campaign coordinator for Medicins Sans Frontieres, a medical humanitarian NGO, says &quot;Access issues are also present in non-communicable lifestyle ailments. This becomes more relevant since developing countries are witnessing an increasing burden of non-communicable diseases, including heart disease, cancer, diabetes, and chronic obstructive pulmonary disease. Hence, generic companies have a big role to play to bring down prices of drugs used in these ailments.&quot; </p>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

Patent war over drugs goes chronic -Rupali Mukherjee

-The Times of India MUMBAI: Turf war between Big Pharma and generic companies, which was largely restricted to exorbitantly priced life-saving drugs for cancer and HIV, is now spilling over to other chronic ailments like diabetes, and threatening to change dynamics of the nearly Rs 70,000 crore Indian pharma market. Triggering a full-blown patent fight with US-based Merck, domestic generic company Glenmark has launched a more affordable version of the multinational's blockbuster anti-diabetes drug Januvia. The move is expected to heighten tensions between MNCs and domestic generic companies which have been embroiled in patent disputes over the last couple of years. Glenmark's launch could also throw up a different patent challenge for the regulators, which have seen two prominent cases where the compulsory licence route was used to launch life-saving drugs at just a fraction of the original price. Glenmark has priced its diabetes drug around 30% cheaper than Merck's Januvia, and the savings to patients could be nearly Rs 5,000 a year. Merck's diabetes therapies Januvia and Janumet, launched in the Indian market in 2008, are part of the 'gliptin' family. The drugs together are nearly Rs 200-crore brands, making them one of the fastest growing medicines, and are ranked No. 2 in the oral diabetics market (according to IMS data). Confirming the move, a company official said, "Glenmark is a responsible company and has launched the products after due diligence and research. Like other branded generics, Glenmark's Zita & Zita-Met are also branded generics." The 'gliptin' market in India is estimated at around Rs 500 crore, growing at 25% per year. 'Gliptin' is an oral once-a-day treatment option. Priced at Rs 43 per tablet, a month's dose of Merck's Januvia costs nearly Rs 1,300. Though 'gliptins' have emerged as a good option in diabetes treatment, their use has been restricted largely because of their high prices, experts say. A MSD India official said; "We are disappointed in Glenmark's decision to introduce products that directly infringe upon our intellectual property. We believe our patents for Januvia and Janumet are valid and enforceable and will vigorously defend them. Strong intellectual property protection is essential for growing India's innovative capacity and economic growth. As an innovative pharmaceutical company, protection of our intellectual property is vital to ensuring that we continue to assume the tremendous monetary risks associated with the discovery of innovative medicines." In India, where there are over 65 million people with type 2 diabetes, MSD also has a comprehensive strategy to help address the challenge of reducing disease burden and to increase access to our medicines, including India-specific responsible pricing for Januvia and Janumet, the official added. While Glenmark says that its product is "non-infringing" on Merck's drug, the details of Merck's patent on the drug sold in the market, were not available. Experts say that Glenmark's move will lead to a protracted legal battle with both sides sticking to their point. Leena Menghaney, legal expert and campaign coordinator for Medicins Sans Frontieres, a medical humanitarian NGO, says "Access issues are also present in non-communicable lifestyle ailments. This becomes more relevant since developing countries are witnessing an increasing burden of non-communicable diseases, including heart disease, cancer, diabetes, and chronic obstructive pulmonary disease. Hence, generic companies have a big role to play to bring down prices of drugs used in these ailments."